股票代码：300363 股票简称：博腾股份 公告编号：2026-010 号 重庆博腾制药科技股份有限公司 关于职工代表大会选举产生第六届董事会职工代表董事 的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 附件： 白银春，男，中国国籍，出生于 1973 年 2 月，硕士。曾担任江苏东台化肥 厂生产调度，上海子能高科股份有限公司技术厂长、生产厂长，上海展昱化工科 技有限公司项目经理。现任公司高级副总经理、首席运营官，负责公司交付体系、 工程、EHS 等相关工作。 截至本公告披露日，白银春先生持有公司股份 156,000 股，占公司总股本的 0.03%，与持有公司 5%以上股份的股东、实际控制人、其他董事、高级管理人 员不存在关联关系；最近 36 个月内白银春先生未受过中国证监会及其他有关部 门的处罚和证券交易所惩戒，不存在《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》第 3.2.3 条所规定的情形，也不是失信被执行 人，符合《公司法》等相关法律、法规和规定要求的任职条件。 白银春先生符合《公司法》等法律法规及《公司章程》规定的有关职 ...

股票代码：300363 股票简称：博腾股份 公告编号：2026-009 号 重庆博腾制药科技股份有限公司 关于实际控制人部分股份质押及解除质押的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 股东名称 | 是否为控股股东 | 本次解除质 | 占其所持 | 占公司总 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 或第一大股东及 | 押股份数量 | 股份比例 | 股本比例 | 起始日 | 解除日期 | 质权人 | | | 一致行动人 | （万股） | (%) | (%) | | | | | 张和兵 | 是 | 156 | 3.72 | 0.29 | 2025-03-25 | 2026-03-17 | 上海海通证 | | 张和兵 | 是 | 25 | 0.60 | 0.05 | 2025-04-09 | 2026-03-17 | 券资产管理 | | 张和兵 | 是 | 521 | 12.43 | 0.96 | 2025-06-06 | 2026-03-17 | 有限公司 | | 陶 ...

股票代码：300363 股票简称：博腾股份 公告编号：2026-008 号 重庆博腾制药科技股份有限公司 关于实际控制人部分股份质押及解除质押的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）于近日接到公司控股 股东、实际控制人之居年丰先生、张和兵先生函告，居年丰先生、张和兵先生将 其持有的公司部分股份分别办理质押及解除质押等业务。具体情况如下： 一、股东股份质押及解除质押基本情况 | | 是否为控 | | 占其所 | 占公司 | 是否为限 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 股股东或 | 本次质 | 持股份 | 总股本 | 售股（如 | 为补 | | | | | | | 第一大股 | 押数量 | | | 是，注明 | | 质押起始日 | 质押到期日 | 质权人 | 质押用途 | | 称 | 东及其一 | （万股） | 比例 | 比例 | 限售类 | 充质 | | ...

重庆博腾制药科技股份有限公司（以下简称"公司"）于 2026 年 2 月 2 日 召开第六届董事会第六次临时会议，审议通过《关于与关联方形成共同投资暨关 联交易的议案》。公司全资子公司重庆博腾生物医学研究院有限公司持有苏州博 腾生物制药有限公司（以下简称"苏州博腾"）42.7818%股权，苏州博航生物技 术中心（有限合伙）（以下简称"苏州博航"）持有苏州博腾 0.0888%股权。苏 州博航的执行事务合伙人苏州博晖生物科技有限责任公司（以下简称"苏州博晖"） 拟将其持有的苏州博航 47.3683%份额（对应 44.9999 万元出资额）转让给陈晖先 生。本次转让完成后，陈晖先生将作为苏州博航的有限合伙人，间接投资苏州博 腾。具体内容详见公司同日于巨潮资讯网披露的《关于与关联方形成共同投资暨 关联交易的公告》（公告编号：2026-004 号）。 | 柳乐 | | 有限合伙人 | 10 | 10.5263 | | --- | --- | --- | --- | --- | | 高凯 | | 有限合伙人 | 10 | 10.5263 | | 仇炜坚 | | 有限合伙人 | 10 | 10.5263 | | 陈凯 | ...

Government Guidance Funds - Shenzhen Innovation Investment Group aims to create a fund cluster with a total scale of 500 billion yuan, focusing on supporting over 1,800 enterprises, with more than 90% in hard technology sectors [3] - Hefei plans to establish three major 10 billion yuan thematic fund clusters with a maximum duration of 20 years, targeting technology innovation and emerging industries [3] - Hong Kong government announced a 10 billion HKD "Innovation and Technology Industry Guidance Fund" to support strategic emerging sectors like life sciences and AI [4] - Macau government plans to launch a guidance fund with an initial investment of 110 million MOP, targeting new industries and technology innovation [5] - Jiangsu Province established a 5 billion yuan special fund focusing on new energy sectors, with over 70% of investments directed towards local projects [5] Market-oriented Funds - Leshan Science and Technology Group is leading the establishment of a 10 billion yuan mother fund to support advanced manufacturing and new energy sectors [10] - The Yangtze River Delta Digital Cultural Industry Fund has been established with a total scale of 100 billion yuan, focusing on AI and digital cultural technology [10] - The Guizhou Aluminum Group has registered a private equity fund with a capital of 2 billion yuan, focusing on local aluminum industry projects [11] - The Qiantang District has signed a 1 billion yuan "chain master" fund focusing on life sciences investments [12] - Granite Asia successfully raised 110 million USD for an AI IPO fund, targeting high-growth AI companies in Asia [12] Industry-specific Funds - Chongqing Boteng Pharmaceutical plans to invest up to 50 million yuan in a private equity fund focused on the cell and gene industry [16] - Zhuhai Hengqin Huajin Deep Integration Technology Venture Capital Fund was established with a capital of 500 million yuan, focusing on private equity investments [13] - Hubei Province established a 5 billion yuan investment fund to support startups in the intelligent airspace sector [15] - Zhejiang University and Chuhua Capital launched a 150 million yuan fund focusing on integrated circuits and high-end manufacturing [14] - The establishment of the Changjiang Doctor Entrepreneurship Fund aims to support high-end doctoral talent projects in Hubei [14]

Core Viewpoint - Boten Co., Ltd. has shown a mixed performance in financing activities and stockholder dynamics, with significant growth in revenue and net profit year-on-year, indicating potential investment opportunities in the pharmaceutical sector [1][2]. Financing Activities - On February 25, Boten Co., Ltd. recorded a financing buy-in amount of 14.66 million yuan, with a net financing outflow of 434,100 yuan, resulting in a total financing balance of 343 million yuan, which constitutes 2.68% of its market capitalization [1]. - The financing balance is below the 10% percentile level over the past year, indicating a low level of financing activity [1]. - In terms of securities lending, there were no shares sold or repaid on February 25, with a remaining short position of 13,400 shares and a balance of 316,200 yuan, also below the 20% percentile level over the past year [1]. Company Performance - As of February 13, the number of shareholders for Boten Co., Ltd. was 42,100, a decrease of 0.68%, while the average circulating shares per person increased by 0.68% to 11,843 shares [2]. - For the period from January to September 2025, Boten Co., Ltd. achieved a revenue of 2.544 billion yuan, representing a year-on-year growth of 19.72%, and a net profit attributable to shareholders of 79.92 million yuan, which is a significant increase of 138.71% year-on-year [2]. Dividend and Shareholder Structure - Since its A-share listing, Boten Co., Ltd. has distributed a total of 1.193 billion yuan in dividends, with 866 million yuan distributed over the past three years [3]. - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited as the fourth largest shareholder with 23.98 million shares, an increase of 13.22 million shares from the previous period [3]. - Tianhong Medical Innovation A ranked as the sixth largest shareholder with 5.94 million shares, a decrease of 458,400 shares, while Huazheng Select Mixed Fund entered as the ninth largest shareholder with 3.78 million shares [3].

Group 1 - The company, Boteng Co., reported that as of February 13, 2026, the total number of shareholders (including both ordinary accounts and margin trading accounts) is 42,122 [2]

Core Viewpoint - Boten Co., Ltd. (300363) has announced its participation in a private equity investment fund, committing up to 50 million RMB, which represents a 3.3333% stake in the fund [1] Group 1: Stock Performance - As of February 24, 2026, Boten Co., Ltd. closed at 23.38 RMB, down 0.09% from the previous trading day [1] - The stock opened at 23.82 RMB, reached a high of 23.91 RMB, and a low of 23.38 RMB, with a trading volume of 1.35 billion RMB and a turnover rate of 1.15% [1] Group 2: Investment Announcement - On February 24, 2026, the company released an announcement regarding its investment in the Shenzhen Songhe Cell and Gene Industry Private Equity Investment Fund [1] - The company’s board approved the investment on February 26, 2025, with a total fund commitment of 150 million RMB, of which Boten Co., Ltd. will contribute 5 million RMB [1] - The fund has completed registration with the China Securities Investment Fund Industry Association and has undergone business registration changes [1]

关于参与认购投资基金份额的进展公告 股票代码：300363 股票简称：博腾股份 公告编号：2026-006 号 重庆博腾制药科技股份有限公司 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2025 年 2 月 26 日召开第五届董事会第三十次临时会议，审议通过《关于拟投资松禾资本细胞与 基因产业基金的议案》。公司拟以自有资金认缴出资不超过 5,000 万元人民币参 与投资深圳市松禾细胞与基因产业私募股权投资基金合伙企业（有限合伙）（以 下简称"基金"）。具体内容详见公司同日于巨潮资讯网披露的《关于参与认购 投资基金份额的公告》（公告编号：2025-004 号）。 二、进展情况 近日，公司收到基金管理人深圳市松禾资本管理有限公司通知，基金已根据 《证券投资基金法》《私募投资基金监督管理暂行办法》等法律法规的要求在中 国证券投资基金业协会完成备案，并完成相关工商变更登记手续，具体登记信息 如下： 名称：深圳市松禾细胞与基因产业私募股权投资基金合伙企业（有限合伙） 统一社会信用代码：91440300M ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]